AR105911A1 - Inhibidores de hdac8 bicíclicos fusionados [6,6] - Google Patents
Inhibidores de hdac8 bicíclicos fusionados [6,6]Info
- Publication number
- AR105911A1 AR105911A1 ARP160102695A ARP160102695A AR105911A1 AR 105911 A1 AR105911 A1 AR 105911A1 AR P160102695 A ARP160102695 A AR P160102695A AR P160102695 A ARP160102695 A AR P160102695A AR 105911 A1 AR105911 A1 AR 105911A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycle
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), y sus sales, profármacos, solvatos, hidratos, isómeros o tautómeros farmacéuticamente aceptables, en donde: Y¹, Y², Y³ e Y⁴ son cada uno, de modo independiente, N, C o CR³, siempre que, cuando unidos a -C(O)NHOH, cualquiera de Y¹, Y², Y³ o Y⁴ sea C; X se selecciona del grupo que consiste en S(O)₂, S(O), S, O, C(=O) y C(R⁴)(R⁵); W es C(R⁴)(R⁵) u O; R¹ es, de modo independiente, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros, -(CH₂)ₙ-Rᵃ, -(CH₂)ₙ-O-(CH₂)ₚ-Rᵃ, -S(O)₂Rᵃ, -C(O)Rᵃ, o -C(O)N(Rᵃ)(Rᵇ), en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo o heterociclo está opcionalmente sustituido con uno o más -OH, halógeno, oxo, -NO₂, -NH₂, -CN, -alquilo C₁₋₆, -alcoxi C₁₋₆, heterociclo, arilo, heteroarilo, o R⁴; Rᵃ es, en cada ocurrencia, hidrógeno, halógeno, OH, NH₂, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros, o -C(O)N(R¹⁰)(R¹¹), en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo, o heterociclo es opcionalmente sustituido con uno o más -OH, R⁴, R⁵, halógeno, oxo, (CH₂)ₙOR⁶, -NO₂, -OR⁶, -N(R⁶)(R⁷), C(O)OR⁶, -C(O)N(R⁶)(R⁷), -S(O)₂R⁶, -S(O)R⁶, -S(R⁶), -C(O)R⁶, S(O)₂N(R⁶)(R⁷), -CN, alquilo -C₁₋₆, haloalquilo -C₁₋₆, alcoxi -C₁₋₆, alquilamino C₁₋₆, dialquilamino C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo C₃₋₈, cicloalquilalquilo C₃₋₈, arilalquilo, heterociclo, arilo, o heteroarilo; Rᵇ es, en cada ocurrencia, hidrógeno, halógeno, OH, NH₂, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros, o -C(O)N(R¹⁰)(R¹¹), en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo, o heterociclo es opcionalmente sustituido con uno o más -OH, R⁴, R⁵, halógeno, oxo, (CH₂)ₙOR⁶, -NO₂, -OR⁶, -N(R⁶)(R⁷), C(O)OR⁶, -C(O)N(R⁶)(R⁷), -S(O)₂R⁶, -S(O)R⁶, -S(R⁶), -C(O)R⁶, -S(O)₂N(R⁶)(R⁷), -CN, alquilo -C₁₋₆, haloalquilo -C₁₋₆, alcoxi -C₁₋₆, alquilamino C₁₋₆, dialquilamino C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo C₃₋₈, cicloalquilalquilo C₃₋₈, arilalquilo, heterociclo, arilo, o heteroarilo; o Rᵃ y Rᵇ se pueden combinar con el carbono o nitrógeno al que están unidos para formar un cicloalquilo C₃₋₈ o heterociclo de 3 a 8 miembros opcionalmente sustituido con uno o más sustituyentes seleccionados de R⁴ y R⁵, en donde R⁴ y R⁵ de modo independiente en cada ocurrencia son H o alquilo -C₁₋₆; R² y R² son, de modo independiente, hidrógeno, alquilo C₁₋₆, alcoxi C₁₋₆, -OH, halógeno, -NO₂, -NH₂, -CN, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros, en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo o heterociclo está opcionalmente sustituido con uno o más -OH, halógeno, oxo, -NO₂, -NH₂, -CN, -alquilo C₁₋₆, -alcoxi C₁₋₆; o R² y R² se pueden combinar con el carbono al que están unidos para formar un grupo oxo, cicloalquilo C₃₋₈ o heterociclo de 3 a 8 miembros; R³ es, de modo independiente, en cada aparición, hidrógeno, halógeno, OH, CN, NO₂, NH₂, alquilo C₁₋₃ o alcoxi C₁₋₃; cada R⁴ o R⁵ es cada uno, de modo independiente, en cada aparición, hidrógeno, halógeno, OH, NH₂, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₄₋₈, arilo, heteroarilo, heterociclo de 3 a 8 miembros o -C(O)N(R¹⁰)(R¹¹), en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, heteroarilo o heterociclo está opcionalmente sustituido con uno o más -OH, R⁴, R⁵, halógeno, oxo, -(CH₂)ₙOR⁶, -NO₂, -OR⁶, -N(R⁶)(R⁷), C(O)OR⁶, -C(O)N(R⁶)(R⁷), -S(O)₂R⁶, -S(O)R⁶, -S(R⁶), -C(O)R⁶, -S(O)₂N(R⁶)(R⁷), -CN, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -alcoxi C₁₋₆, alquil C₁₋₆-amino, dialquil C₁₋₆-amino, hidroxi C₁₋₆-alquilo, cicloalquilo C₃₋₈, cicloalquil C₃₋₈-alquilo, arilalquilo, heterociclo, arilo o heteroarilo; o R⁴ y R⁵ se pueden combinar con el carbono o nitrógeno al que están unidos para formar un grupo oxo, cicloalquilo C₃₋₈ o heterociclo de 3 a 8 miembros, opcionalmente sustituido con uno o más sustituyentes seleccionados de R⁴ y R⁵, en donde R⁴ y R⁵, de modo independiente, en cada ocurrencia, son H o alquilo -C₁₋₆; o R⁴ y R⁵ juntos cuando se unen al mismo átomo forman un anillo spirocicloalquilo C₃₋₈; o R⁴ y R⁵ juntos cuando se unen al mismo átomo forman un anillo spiroheterocicloalquilo C₃₋₈; o R⁴ y R⁵ juntos cuando se unen a átomos adyacentes forman un anillo arilo, un anillo heteroarilo, un anillo cicloalquilo C₃₋₈, o un heterociclo de 3 a 8 miembros, en donde el spirocicloalquilo, spiroheterocicloalquilo, heteroarilo, cicloalquilo o heterociclo son sustituidos opcionalmente con uno o más grupos seleccionados de OH, halógeno, alquilo -C₁₋₆ o C(O)OR⁶; R⁶ y R⁷ están seleccionados cada uno, de modo independiente, del grupo que consiste en hidrógeno, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₆, amino, alquilamino C₁₋₆, dialquilamino C₁₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₃₋₈, arilo, heteroarilo, heterociclo, -S(O)₂NR⁸R⁹, -S(O)₂R⁸, -C(O)R⁸, -CO₂R⁸, -S(O)R⁸ o -S(O)NR⁸R⁹, en donde cada alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, fenilo, heteroarilo o heterociclo está opcionalmente sustituido con uno o más -OH, halógeno, oxo, -NO₂, -NH₂, -CN, -alquilo C₁₋₆, -alcoxi C₁₋₆, alquil C₁₋₆-amino, dialquil C₁₋₆-amino, hidroxi C₁₋₆-alquilo, heterociclo, arilo, heteroarilo; o R⁶ y R⁷ junto con un átomo al que están unidos forman un cicloalquilo C₃₋₈ o un heterociclo de 3 a 8 miembros, en donde el cicloalquilo o el heterociclo es sustituido opcionalmente con uno o más grupos seleccionados de halógeno, oxo y alquilo C₁₋₆; R⁸ y R⁹ son cada uno, de modo independiente, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, cicloalquenilo C₃₋₈, heteroarilo o heterociclo de 3 a 8 miembros, en donde cada uno está opcionalmente sustituido con uno o más -OH, halógeno, oxo, -NO₂, -NH₂, -CN, -alquilo C₁₋₆, -alcoxi C₁₋₆, alquil C₁₋₆-amino, dialquil C₁₋₆-amino, hidroxi C₁₋₆-alquilo, heterociclo, arilo o heteroarilo; R¹⁰ y R¹¹ son cada uno, de modo independiente, hidrógeno, alquilo C₁₋₆, arilo, alquil C₁₋₆-arilo o heterociclo de 3 a 8 miembros; en donde arilo, arilalquilo y heterociclo son sustituidos opcionalmente con uno o más grupos seleccionados de halógeno, alquilo C₁₋₆, y alcoxi C₁₋₆; o R¹⁰ y R¹¹ se pueden combinar para formar un heterociclo de 3 a 8 miembros opcionalmente sustituido con uno o más R¹²; R¹² es H o alquilo C₁₋₆ o dos adyacentes R¹² se pueden combinar para formar un grupo arilo o heteroarilo; n es un número entero de 1 a 6; y p es un número entero de 0 a 2; siempre que el compuesto no sea N-hidroxi-1-((4-metoxifenil)sulfonil)-1,2,3,4-tetrahidroquinolin-6-carboxamida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562214101P | 2015-09-03 | 2015-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105911A1 true AR105911A1 (es) | 2017-11-22 |
Family
ID=56920943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102695A AR105911A1 (es) | 2015-09-03 | 2016-09-02 | Inhibidores de hdac8 bicíclicos fusionados [6,6] |
Country Status (4)
Country | Link |
---|---|
US (5) | US10029995B2 (es) |
AR (1) | AR105911A1 (es) |
TW (1) | TW201711999A (es) |
WO (1) | WO2017040963A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160083343A1 (en) | 2013-03-15 | 2016-03-24 | Global Blood Therapeutics, Inc | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
MX2017011778A (es) | 2015-03-13 | 2017-12-04 | Forma Therapeutics Inc | Compuestos y composiciones de alfa-cinamida como inhibidores de histona desacetilasa 8 (hdac8). |
TW201711999A (zh) | 2015-09-03 | 2017-04-01 | 佛瑪治療公司 | ﹝6,6﹞稠合雙環組蛋白脫乙醯基酶8(hdac8)抑制劑 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
UA125730C2 (uk) | 2017-06-22 | 2022-05-25 | Курадев Фарма Лімітед | Низькомолекулярні модулятори sting людини |
EP3642184A1 (en) * | 2017-06-22 | 2020-04-29 | Curadev Pharma Limited | Small molecule modulators of human sting |
JP2020530443A (ja) * | 2017-07-24 | 2020-10-22 | イソキュア バイオサイエンシーズ インク. | 突然変異体イソクエン酸デヒドロゲナーゼの阻害剤、及びその組成物、並びに方法 |
GB2568549A (en) * | 2017-11-21 | 2019-05-22 | Univ Leicester | New compounds and uses |
KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
CN109761968A (zh) * | 2018-12-25 | 2019-05-17 | 河南师范大学 | 具有抗肿瘤活性的丹皮酚并苯并噁嗪类化合物及其制备方法和应用 |
CR20220363A (es) | 2019-12-27 | 2022-09-23 | Lupin Ltd | Compuestos tricíclicos sustituidos |
US20240051931A1 (en) * | 2020-12-03 | 2024-02-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Hdac inhibitors |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5234923A (en) | 1991-12-16 | 1993-08-10 | E. R. Squibb & Sons, Inc. | Substitute indole and benzimidazole derivatives |
WO1993015066A1 (en) | 1992-01-23 | 1993-08-05 | Pfizer Inc. | Benzopyran and related ltb4 antagonists |
US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
US5393771A (en) | 1993-05-12 | 1995-02-28 | Brisol-Myers Squibb Company | 4-substituted benzopyran and related compounds |
AU704114B2 (en) | 1993-11-18 | 1999-04-15 | Siga Technologies, Inc. | Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
KR0125117B1 (ko) | 1994-06-15 | 1997-12-05 | 성재갑 | 항 에이즈(aids)효과를 갖는 신규한 인간 면역 결핍 바이러스(hiv)프로테아제 억제 화합물 및 그의 제조방법 |
MY113463A (en) | 1994-01-04 | 2002-03-30 | Novo Nordisk As | Novel heterocyclic compounds |
CA2201742A1 (en) | 1994-10-13 | 1996-04-25 | Anthony Daniel Piscopio | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4 (ltb4) antagonists |
EP0785935A1 (en) | 1994-10-13 | 1997-07-30 | Pfizer Inc. | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4' (ltb4) antagonists |
CA2217194A1 (en) | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel heterocyclic compounds |
WO1996031473A1 (en) | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel heterocyclic compounds |
WO1996031500A1 (en) | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel heterocyclic compounds |
WO1996031470A1 (en) | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel heterocyclic compounds |
WO1996031503A1 (en) | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel heterocyclic compounds |
DE69622031T2 (de) | 1995-04-10 | 2002-12-12 | Fujisawa Pharmaceutical Co | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN |
AU3166897A (en) | 1996-06-24 | 1998-01-14 | Novo Nordisk A/S | Factor vii-binding reagent |
JPH10259176A (ja) * | 1997-03-17 | 1998-09-29 | Japan Tobacco Inc | 血管新生阻害作用を有する新規アミド誘導体及びその用途 |
US6461610B1 (en) | 1997-07-18 | 2002-10-08 | Novo Nordisk A/S | Methods for modifying cell motility using factor VIIa or inactivated factor VIIa |
EP1005361B1 (en) | 1997-07-18 | 2010-01-06 | Novo Nordisk Health Care AG | USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY |
IL128731A0 (en) | 1998-03-12 | 2000-01-31 | Pfizer Prod Inc | Method of preventing allograft rejection |
EP0963755A3 (en) | 1998-04-16 | 2001-03-14 | Pfizer Products Inc. | Use of benzopyranes for preventing allograft rejection |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
WO2000068230A1 (en) | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors |
EP1255743A1 (en) | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa |
EP1255741A2 (en) | 2000-02-01 | 2002-11-13 | Cor Therapeutics, Inc. | 2- 1H]-QUINOLONE AND 2- 1H]-QUINOXALONE INHIBITORS OF FACTOR Xa |
CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
ATE309996T1 (de) | 2000-09-11 | 2005-12-15 | Chiron Corp | Chinolinonderivate als tyrosin-kinase inhibitoren |
AU2001293835A1 (en) | 2000-09-25 | 2002-04-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives |
AU2002306687A1 (en) | 2001-03-13 | 2002-09-24 | Glenmark Pharmaceuticals Limited | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them |
US7615640B2 (en) | 2002-07-29 | 2009-11-10 | Mitsubishi PaperMillsLtd. | Organic dye, photoelectric conversion material, semiconductor electrode and photoelectric conversion device |
EP2374455A3 (en) | 2004-08-19 | 2012-03-28 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
ITRM20050390A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
WO2007024944A1 (en) | 2005-08-25 | 2007-03-01 | Schering Corporation | Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
EP1940805A4 (en) | 2005-08-26 | 2009-11-11 | Methylgene Inc | BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE |
US7858635B2 (en) | 2005-12-22 | 2010-12-28 | Vertex Pharmaceuticals Incorporated | Spiro compounds as modulators of muscarinic receptors |
WO2008030120A1 (en) | 2006-09-07 | 2008-03-13 | Auckland Uniservices Limited | A method for the fluorescent detection of nitroreductase activity using nitro-substituted aromatic compounds |
JP5583406B2 (ja) | 2006-10-28 | 2014-09-03 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
WO2008059339A2 (en) | 2006-11-13 | 2008-05-22 | Glenmark Pharmaceuticals S.A. | Isoquinoline derivatives as vanilloid receptor modulators |
WO2008124300A1 (en) | 2007-04-10 | 2008-10-16 | National Health Research Institutes | Hepatitis c virus inhibitors |
WO2008141980A1 (en) | 2007-05-24 | 2008-11-27 | Basf Se | Substituted amino-thiourea compounds for combating animal pests |
US9493419B2 (en) | 2007-08-21 | 2016-11-15 | The Hong Kong Polytechnic University | Quinoline derivatives as anti-cancer agents |
US20090136461A1 (en) | 2007-11-28 | 2009-05-28 | Moon Suk Kim | Neuronal differentiation method of adult stem cells using small molecules |
MY155517A (en) | 2008-03-31 | 2015-10-30 | C&C Res Lab | Heterocyclic derivatives |
GB0818366D0 (en) | 2008-10-07 | 2008-11-12 | Argenta Discovery Ltd | Quinolin-2-one-compounds |
KR101051057B1 (ko) | 2008-11-11 | 2011-07-21 | 한국화학연구원 | 신경전구세포 또는 줄기세포의 신경세포로의 분화 유도용 조성물 및 방법 |
TW201022279A (en) | 2008-11-14 | 2010-06-16 | Astrazeneca Ab | Chemical compounds |
US8791090B2 (en) | 2009-03-31 | 2014-07-29 | Kowa Company, Ltd. | Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient |
WO2011002520A2 (en) | 2009-07-02 | 2011-01-06 | Angion Biomedica Corp. | Small molecule inhibitors of parp activity |
JP2011148714A (ja) | 2010-01-19 | 2011-08-04 | Nippon Soda Co Ltd | 病害防除方法 |
JP2013525400A (ja) | 2010-04-28 | 2013-06-20 | バイエル・クロップサイエンス・アーゲー | 殺菌剤ヒドロキシモイル−複素環誘導体 |
WO2012001040A1 (en) | 2010-07-02 | 2012-01-05 | Syngenta Participations Ag | Novel microbiocidal dioxime ether derivatives |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
RU2577861C2 (ru) | 2010-09-09 | 2016-03-20 | Ф. Хоффманн-Ля Рош Аг | N-гидрокси-бензамиды для лечения рака |
US8765773B2 (en) | 2010-10-18 | 2014-07-01 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
WO2012117421A1 (en) | 2011-03-02 | 2012-09-07 | Orchid Research Laboratories Ltd | Histone deacetylase inhibitors |
WO2012117021A2 (en) | 2011-03-03 | 2012-09-07 | Syngenta Participations Ag | Novel microbiocidal oxime ethers |
WO2012137224A1 (en) | 2011-04-05 | 2012-10-11 | University Of Delhi | Coumarin compounds for the treatment of mycobacterial infections |
KR102036199B1 (ko) | 2011-08-17 | 2019-10-24 | 메르크 앤드 씨에 | 알부민-결합 개체들의 폴레이트 공액체들 |
WO2013026842A1 (en) | 2011-08-22 | 2013-02-28 | Merck & Cie | 18f-saccharide-folates |
WO2013059582A2 (en) * | 2011-10-20 | 2013-04-25 | Nupotential, Inc. | Small molecule inhibitors of histone deacteylases |
WO2013059852A1 (en) | 2011-10-25 | 2013-05-02 | Kernaghan Gregory Lawrence | Method of improving the acoustic response of musical instruments |
WO2013092460A1 (en) | 2011-12-20 | 2013-06-27 | Syngenta Participations Ag | Cyclic bisoxime microbicides |
CA2876370A1 (en) | 2012-07-12 | 2014-01-16 | Viiv Healthcare Uk Limited | Compounds and methods for treating hiv |
EP2970127B1 (en) | 2013-03-14 | 2018-10-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors |
JP2016147807A (ja) | 2013-06-04 | 2016-08-18 | 日本理化学工業株式会社 | ヒドロキサム酸誘導体またはその塩 |
TW201636329A (zh) | 2015-02-02 | 2016-10-16 | 佛瑪治療公司 | 作為hdac抑制劑之雙環[4,6,0]異羥肟酸 |
CA2975605C (en) | 2015-02-02 | 2023-12-12 | Forma Therapeutics, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
MX2017011778A (es) | 2015-03-13 | 2017-12-04 | Forma Therapeutics Inc | Compuestos y composiciones de alfa-cinamida como inhibidores de histona desacetilasa 8 (hdac8). |
TW201643139A (zh) | 2015-04-17 | 2016-12-16 | 佛瑪治療公司 | 作為組蛋白脫乙醯基酶抑制劑之3-螺環-6-異羥肟酸萘滿 |
TW201711999A (zh) | 2015-09-03 | 2017-04-01 | 佛瑪治療公司 | ﹝6,6﹞稠合雙環組蛋白脫乙醯基酶8(hdac8)抑制劑 |
EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
-
2016
- 2016-09-02 TW TW105128502A patent/TW201711999A/zh unknown
- 2016-09-02 AR ARP160102695A patent/AR105911A1/es unknown
- 2016-09-02 US US15/255,817 patent/US10029995B2/en active Active
- 2016-09-02 WO PCT/US2016/050152 patent/WO2017040963A1/en active Application Filing
-
2018
- 2018-06-08 US US16/003,861 patent/US10370343B2/en active Active
-
2019
- 2019-06-24 US US16/449,675 patent/US10829460B2/en active Active
-
2020
- 2020-10-08 US US17/066,385 patent/US11414392B2/en active Active
-
2023
- 2023-01-13 US US18/096,712 patent/US20230406830A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11414392B2 (en) | 2022-08-16 |
TW201711999A (zh) | 2017-04-01 |
US20230406830A1 (en) | 2023-12-21 |
US10029995B2 (en) | 2018-07-24 |
US20210139439A1 (en) | 2021-05-13 |
US20180354919A1 (en) | 2018-12-13 |
WO2017040963A1 (en) | 2017-03-09 |
US10370343B2 (en) | 2019-08-06 |
US20190308946A1 (en) | 2019-10-10 |
US10829460B2 (en) | 2020-11-10 |
US20170066729A1 (en) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR105911A1 (es) | Inhibidores de hdac8 bicíclicos fusionados [6,6] | |
AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
AR108356A1 (es) | Derivados aromáticos de sulfonamida | |
AR099824A1 (es) | Compuestos bicíclicos | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR081204A1 (es) | Pirrolopirazinas como inhibidores de quinasas | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
PE20212253A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
AR107293A1 (es) | COMPUESTOS DE PIRIDINA Y PIRIDIMINA COMO INHIBIDORES DE PI3K-g | |
AR104415A1 (es) | Compuestos antiestrogénicos derivados de cromeno | |
AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
AR108864A1 (es) | Agentes antibacterianos | |
AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
AR115906A1 (es) | Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas | |
AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
AR113227A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
HRP20080097T5 (en) | Piperazine derivatives and their use as serotonin reuptake inhibitors or as neurokinin antagonists | |
AR098528A1 (es) | Derivados imidazol | |
AR104261A1 (es) | Derivados de indol | |
AR116973A1 (es) | Compuestos de organoazufre |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |